Travere Therapeutics (TVTX) just secured full FDA approval for FILSPARI in focal segmental glomerulosclerosis without nephrotic syndrome, extending its use beyond IgA nephropathy and reshaping how investors may think about the company’s rare kidney portfolio.

The FDA decision arrives alongside a sharp 46.95% 1 month share price return and a 37.57% 3 month share price return, while the 1 year total shareholder return of 120.95% points to strong momentum rather than a short lived reaction.

If you are looking for more ideas in healthcare and beyond, this is a good moment to see what else is moving with 33 healthcare AI stocks.

With Travere now valued at about US$3.8b and trading around US$40.50 versus an average analyst target near US$49.60, alongside an indicated intrinsic discount of roughly 54%, investors have to ask whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 4.7% Undervalued

At a last close of $40.50 versus a widely followed fair value of $42.50, the dominant Travere narrative frames recent FDA progress as the anchor for that gap.

Travere's strengthening financial position, driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management, sets a foundation for positive net earnings, while securing resources for continued pipeline development and future commercial launches. (Earnings, cash flow, R&D investment)

Want to see how this story translates into numbers? The narrative leans on fast revenue expansion, rising margins and a richer future earnings multiple to reach that fair value.

The analysis behind this fair value uses a 7.29% discount rate and incorporates strong revenue and earnings growth expectations, alongside a higher future P/E multiple than the broader US biotech peer group. Together, those inputs bridge the gap between Travere's current loss making status and the earnings profile implied in the $42.50 figure.

Result: Fair Value of $42.50 (UNDERVALUED)

However, this hinges on FILSPARI continuing to convert its broader label into revenue, provided that competition, pricing pressure, and heavy R&D and SG&A spending remain manageable.

Another View: Multiples Send A Different Signal

The fair value narrative leans on future cash flows and a 7.29% discount rate, but the current P/S of 7.6x tells a different story. It sits below the US biotech average of 11.4x yet above a fair ratio of 5.8x, which points to both upside potential and valuation risk if sentiment changes.

To see how this price gap relates to the earnings story, it is worth looking at what the numbers imply over time, not just today, in our valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed around valuation, risks, and rewards, this is the time to review the data yourself and move quickly so your view is grounded in facts, starting with 4 key rewards and 2 important warning signs.

Ready for more stock ideas?

If you stop with just one company, you might miss opportunities that suit your risk level, income needs, or preference for quality balance sheets and underappreciated names.

• Spot potential mispricing early by reviewing companies highlighted in the 56 high quality undervalued stocks that combine quality fundamentals with room for sentiment to catch up.
• Build a steadier income stream by checking out companies in the 13 dividend fortresses that focus on higher yields with a focus on resilience.
• Sleep easier at night by scanning the 72 resilient stocks with low risk scores for businesses that score well on financial strength and lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.